INSIGHTS ON UPSTREAM MANUFACTURING
-
Designing ADC Manufacturing For Operator And Patient Safety
ADC manufacturing succeeds when manufacturability is treated as an early design input. Cell line choices, toxic payload handling, and single-use extractables each shape operator exposure and risk.
-
Flexible Automation For Bioprocess Development And Quality Control
Flexible lab automation can standardize experimentation across upstream process engineering and downstream quality control, while staying adaptable as process requirements shift.
-
Expanding The Transposase Toolkit For Cell Line Engineering
Combining distinct transposase systems in one cell line opens engineering options beyond single-system insertion, including control over glycosylation, enzymatic function, and more.
-
Rethinking Expression To Accelerate Antibody Discovery
Expression often limits high-throughput antibody discovery because functional screening needs soluble, correctly folded protein. Explore how moving expression into screening changes which candidates get tested.
-
Exciting Advances In Cell Line Development11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., discuss the trends or advancements that excite them the most, which include a deeper understanding of CHO cell biology and the industry-wide push towards continuous manufacturing.
-
When To Shift To A Master Cell Bank11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., answer audience questions pertaining to master cell banking (MCB) and technology transfer.
-
Clone Selection And CMC Documentation11/5/2026
This closing segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” focuses on clone selection and the regulatory importance of demonstrating clonality in cell line development (CLD). Panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., also share their thoughts on Operation Trial Blazer.
-
Properly Documenting Early Cell Line Development11/5/2026
In this segment from the Bioprocess Online Live event, “Critical Decisions Driving Next-Generation Cell Line Development,” panelists Ted Peters, Ph.D., and Ronan O’Kennedy, Ph.D., agree that documentation (or rather, failing to document) is the most common issue they’ve encountered teams make in cell line development (CLD). They both believe teams should spend more time correctly documenting early CLD and understanding regulatory requirements ahead of IND submission.
UPSTREAM MANUFACTURING SOLUTIONS
-
Successful targeted oncology programs combine biological engineering, potent compound synthesis, and efficient manufacturing to reduce complexity and speed clinical progress.
-
Bead-free activation of human T cells through biodegradable nanoparticles aims to protect cell health during expansion, with the reagent cleared by simple washing or centrifugation.
-
Cell expansion built around low seeding requirements and high yields in 1 L or less. A bioreactor design drawn from human biology aims to simplify scale-up.
-
De-risk biotech development with guaranteed tech transfer and process support. Safeguard your investment from cell line development through protein optimization.
-
Scaling adherent cell culture from flasks to multilayer systems depends on surface consistency, aseptic connections, and more. See how ultrasonic welding and retention hardware shape that path.